Method for the treatment of narcotic withdrawal symptoms in animals using lipopolysaccharides
US5413993A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Aug 20, 1992 |
| Grant date | May 9, 1995 |
| Priority date | — |
| Expiry date | Aug 20, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/822
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antiwithdrawal agents and veterinary antiwithdrawal agents are disclosed which contain lipopolysaccharide (LPS) representatives which have the following physical properties: PA0 LPS1 Dominant molecular weight: 5,000.+-.1,000 as determined by SDS-PAGR method ______________________________________ Phosphorus number: 2 .+-. 1/5,000 (m.w.) Hexosamine number: 9 .+-. 1/5,000 (m.w.) KDO number: 2 .+-. 1/5,000 (m.w.); ______________________________________ PA0 LPS2 Dominant molecular weight: 6,500.+-.2,500 as determined by SDS-PAGR method ______________________________________ Phosphorus number: 1 to 2/5,000 (m.w.) Hexosamine number: 7 .+-. 1/5,000 (m.w.) KDO number: 1 to 2/5,000 (m.w.); and ______________________________________ PA0 LPS3 Dominant molecular weight:6,500.+-.2,500 as determined by SDS-PAGE method ______________________________________ Phosphorus number: 2 .+-. 1/5,000 (m.w.) Hexosamine number: 5 .+-. 1/5,000 (m.w.) KDO number: 2 .+-. 1/5,000 (m.w.) ______________________________________ Furthermore LPS1, LPS2 and LPS3 are used in a method of treating narcotic withdrawal symptoms in an animal host.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.